Happy, your response reminded me that the MHRA's funding is provided for the most part by pharmaceutical companies, so if I put on my cynical (realist) hat, it's a possibility that one or more of the BPs could imply it may withhold or delay funding based on approval. I'm also reminded of a story on how bureaucracies can delay on sidetrack the process. In that case the story was that when A got a request, he filed it. Held until he got a follow-up, dropped it in a second folder. Held until received a second request, dropped in a 3rd folder. When a third request was received, forwarded it to the next person up the line.
Market Data 
Markets 
